These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18794387)

  • 1. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
    Hafner V; Albermann N; Haefeli WE; Ebinger F
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
    Yanni SB; Annaert PP; Augustijns P; Ibrahim JG; Benjamin DK; Thakker DR
    Drug Metab Dispos; 2010 Jan; 38(1):25-31. PubMed ID: 19841059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous voriconazole after toxic oral administration.
    Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
    Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
    Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerated metabolism of voriconazole and its partial reversal by cimetidine.
    Moriyama B; Elinoff J; Danner RL; Gea-Banacloche J; Pennick G; Rinaldi MG; Walsh TJ
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1712-4. PubMed ID: 19171800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of cerebral aspergillosis successfully treated with voriconazole.
    de Lastours V; Lefort A; Zappa M; Dufour V; Belmatoug N; Fantin B
    Eur J Clin Microbiol Infect Dis; 2003 May; 22(5):297-9. PubMed ID: 12740666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
    Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
    Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
    Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
    J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcome in central nervous system aspergillosis.
    Tattevin P; Le Tulzo Y
    Blood; 2006 Apr; 107(8):3410-1; author reply 3411-2. PubMed ID: 16597600
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical importance of the CYP2C19*17 variant allele for voriconazole.
    Dolton MJ; McLachlan AJ
    Br J Clin Pharmacol; 2011 Jan; 71(1):137-8. PubMed ID: 21143511
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.